Condition: Metastatic Breast Cancer · Metastatic Solid Cancer · Sponsor: Abscint NV/SA
This phase II study aims to confirm the diagnostic performance and accuracy of 68Ga-ABS011 PET/CT in determining the HER2 expression status, and to evaluate 68Ga-ABS011's ability to drive changes in therapeutic treatment. 68Ga-ABS011 will be compared to the current standard of care (SOCa) diagnostic methods including immunohistochemistry (IHC), in situ hybridization (ISH) and imaging tools used for treatment response follow-up including Fluorodeoxyglucose F-18 (18F-FDG) positron emitted tomography (PET) and contrast enhanced computed tomography (ceCT).
This description comes directly from the study's public registry record.
Karine Clauwaert · +32476536594 · karine.clauwaert@abscint.com
Dieter Frijns · +32473337625 · dieter.frijns@abscint.com
Always discuss trial participation with your own doctor first.
| Medizinische Universität Innsbruck | Innsbruck, Tyrol, Austria | Recruiting |
| AZ Delta CHIREC | Brussels, Brussels Capital, Belgium | Recruiting |
| Cliniques Universitaires Saint-Luc | Brussels, Brussels Capital, Belgium | Recruiting |
| Free University Brussels (VUB) | Brussels, Brussels Capital, Belgium | Recruiting |
| Institut Jules Bordet | Brussels, Brussels Capital, Belgium | Recruiting |
| OLV Aalst | Aalst, East-Flanders, Belgium | Completed |
| University Hospital Gasthuisberg | Leuven, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06369831